Does Medicare Cover Zepbound?
Zepbound is approved for weight loss and for sleep apnea, and Medicare treats the two uses differently. There are three ways it can be covered in 2026.
It depends on why it's prescribed. Medicare Part D generally does not cover Zepbound (tirzepatide) for weight loss alone, because federal law excludes weight-loss drugs from Part D. Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and some plans cover it for that diagnosis. Since July 1, 2026, a temporary program called the Medicare GLP-1 Bridge has covered the Zepbound KwikPen for weight loss at a $50 monthly copay. It runs through the end of 2027.
The FDA has approved Zepbound for two uses: chronic weight management, and moderate-to-severe obstructive sleep apnea (OSA) in people with obesity. Medicare's exclusion applies only to the weight-loss use. That leaves two routes to coverage: the sleep apnea diagnosis and the Bridge program.
| Why it's prescribed | Covered by Medicare? | What you need |
|---|---|---|
| Weight loss only, standard Part D | No | Not available. The law excludes weight-loss drugs. |
| Obstructive sleep apnea with obesity | Sometimes | Zepbound on your plan's formulary, a sleep study, and prior authorization. |
| Weight loss through the GLP-1 Bridge | Yes, through Dec 31, 2027 | A participating plan, the KwikPen form, and prior authorization. $50 per 30-day supply. |
Why weight loss alone usually isn't covered
Part D has excluded drugs used for weight loss since the program began. The exclusion is written into the statute and is based on what the drug is used for. A patient's own health risks from obesity do not change it. When weight management is the diagnosis on the prescription, a Part D plan generally cannot pay for Zepbound outside the Bridge program.
The sleep apnea pathway
In late 2024, the FDA added an approval for moderate-to-severe obstructive sleep apnea in adults with obesity. OSA is a separate medical condition, so this use is outside the weight-loss exclusion. A Part D or Medicare Advantage plan is allowed to cover Zepbound for OSA. Each plan decides whether to do so.
What's typically required
A documented diagnosis of moderate-to-severe obstructive sleep apnea, usually confirmed by a sleep study, plus obesity as a co-occurring condition.
Prior authorization
Most plans that cover Zepbound for OSA require prior authorization, with your doctor submitting the sleep study results and diagnosis codes.
Formulary variation
Not every Part D or Medicare Advantage plan lists Zepbound on its formulary, even for OSA. Each plan decides.
Cost if approved
Standard Part D cost-sharing applies: your plan's deductible and the copay for the drug's tier, the same as for other covered brand-name drugs.
The Medicare GLP-1 Bridge program
The Medicare GLP-1 Bridge is a temporary CMS demonstration that began July 1, 2026. It is open to eligible members of participating Part D and Medicare Advantage drug plans. It covers certain GLP-1 drugs for weight loss, namely Wegovy, Foundayo and the Zepbound KwikPen, for a flat $50 copay per 30-day supply. The program runs through December 31, 2027. CMS plans to move to a longer-term model after that.
Check three things before you count on it for Zepbound:
- The form of the drug. Only the KwikPen is included. The single-dose pen and the vials are not.
- Your plan. Your Part D or Medicare Advantage drug plan has to take part in the Bridge.
- Eligibility. You need prior authorization and have to meet the program's criteria, which are based on weight and obesity-related health conditions.
How to check your specific plan
Search your plan's formulary for "tirzepatide" or "Zepbound." Then call member services and ask:
- Is Zepbound covered under my plan, and for which diagnosis?
- Does it need prior authorization?
- Which tier is it on, and what will I pay?
- Does my plan participate in the Medicare GLP-1 Bridge?
If Zepbound is prescribed for sleep apnea, ask your doctor's office to send your sleep study results with the prior authorization request. Plans usually decide on that evidence.
Open enrollment runs from October 15 to December 7. If your current plan does not cover Zepbound for your diagnosis, you can compare 2027 formularies during that window.
Frequently Asked Questions
Does Medicare cover Zepbound for weight loss?
Not through standard Part D coverage, because federal law excludes weight-loss drugs from Part D. Since July 1, 2026, the temporary Medicare GLP-1 Bridge program has covered the Zepbound KwikPen for weight loss at a $50 monthly copay for eligible members of participating plans. It runs through December 31, 2027.
Does Medicare cover Zepbound for sleep apnea?
It can. Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, which is a separate medical condition from weight loss. Some Part D plans cover it for this use if it is on their formulary and they approve prior authorization confirming the OSA diagnosis.
What's the difference between Zepbound and Mounjaro?
Both contain tirzepatide and come from the same manufacturer, but they are approved for different uses. Mounjaro is approved for type 2 diabetes and is typically covered by Part D like other diabetes drugs. Zepbound is approved for weight management and sleep apnea, so the weight-loss exclusion applies unless it is prescribed for sleep apnea or covered through the Bridge program.
Which Zepbound formulation is covered under the GLP-1 Bridge?
Only the Zepbound KwikPen. The single-dose pen and vial formulations are not included in the Bridge program as of 2026.
How do I find out if my plan covers Zepbound?
Check your Part D or Medicare Advantage plan's formulary for tirzepatide or Zepbound. Or call member services and ask whether it is covered, for which diagnosis, which tier it is on, and whether your plan participates in the GLP-1 Bridge program.
This article is for general educational purposes and reflects Medicare rules as of October 2026. It is not medical or insurance advice. Coverage depends on your diagnosis, prescription and plan. Confirm the details with your doctor and your Medicare Part D or Medicare Advantage plan.